Ambagon Therapeutics




San Francisco, CA
AmbAgon Therapeutics develops first-in-class small-molecule therapeutics for cancer by augmenting the tumor-suppressing functions of the 14-3-3 protein, a truly novel approach for inhibiting oncogenic transcription factors for cancers with defined drivers, such as breast cancer. AmbAgon combines unique expertise in 14-3-3 drug discovery towards previously undruggable targets with a broad platform technology and industry experience to discover the next generation of anticancer therapies.

Michelle Arkin

Christian Ottman

Lucas Brunsveld

Stay Tuned

Subscribe to our newsletter and get updates on our portfolio companies.